Autophagy is involved in a clearance of anti-cancer agent doxorubicin in the multidrug resistant cancer cell line.

Research Project

Project/Area Number	25670083
Research Category	Grant-in-Aid for Challenging Exploratory Research
Allocation Type	Multi-year Fund
Research Field	Medical pharmacy
Research Institution	Nagahama Institute of Bio-Science and Technology
Principal Investigator	NARA Atsuki 長浜バイオ大学, バイオサイエンス学部, 講師 (60387959)
Project Period (FY)	2013-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000) Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	薬剤耐性 / オートファジー / ドキソルビシン / 抗がん剤排除
Outline of Final Research Achievements	Release of drug from the cancer cells contributes reduction of its cytotoxicity. How are the chemotherapeutic agents that accumulated in the cells released to the extracellular space? In my study, I tried to examine about a direct involvement of autophagy in anti-cancer drug doxorubicin delivery. The study provides a novel insight for an autophagic delivery of doxorubicin from the nucleus to the lysosomes in multidrug resistant cancer cell line.